Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

Author： Jamal-Hanjani Mariam   Pettengell Ruth  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.7, Iss.11, 2011-11, pp. : 1441-1448

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pixantrone for the treatment of aggressive non-Hodgkin lymphoma

By Mukherji Deborah   Pettengell Ruth  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 11, 2010-08 ,pp. : 1915-1923

Informa Healthcare

Access to resources Recommend Favorite

The role of pixantrone in the treatment of non-Hodgkin’s lymphoma

By Borchmann Peter  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 8, 2005-08 ,pp. : 1055-1061

Informa Healthcare

Access to resources Recommend Favorite

Pixantrone tops doxorubicin for non-Hodgkin's lymphoma

By  

Inpharma, Vol. 1, Iss. 1619, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas

By El-Helw Loaie M   Hancock Barry W  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 10, 2007-10 ,pp. : 1683-1691

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma

By Fanale Michelle A.   Younes Anas  

Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. : 333-350

Adis International

Access to resources Recommend Favorite